Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment trial</title><author><name sortKey="Baxter, Jd" sort="Baxter, Jd" uniqKey="Baxter J" first="Jd" last="Baxter">Jd Baxter</name><affiliation><nlm:aff id="A1">Cooper University Hospital/Cooper Medical School of Rowan University, Camden, NJ, USA</nlm:aff></affiliation></author><author><name sortKey="Dunn, D" sort="Dunn, D" uniqKey="Dunn D" first="D" last="Dunn">D. Dunn</name><affiliation><nlm:aff id="A2">Medical Research Council Clinical Trials Unit at UCL, London, UK</nlm:aff></affiliation></author><author><name sortKey="White, E" sort="White, E" uniqKey="White E" first="E" last="White">E. White</name><affiliation><nlm:aff id="A2">Medical Research Council Clinical Trials Unit at UCL, London, UK</nlm:aff></affiliation></author><author><name sortKey="Sharma, S" sort="Sharma, S" uniqKey="Sharma S" first="S" last="Sharma">S. Sharma</name><affiliation><nlm:aff id="A3">Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA</nlm:aff></affiliation></author><author><name sortKey="Geretti, Am" sort="Geretti, Am" uniqKey="Geretti A" first="Am" last="Geretti">Am Geretti</name><affiliation><nlm:aff id="A4">Institute of Infection and Global Health, University of Liverpool, UK</nlm:aff></affiliation></author><author><name sortKey="Kozal, Mj" sort="Kozal, Mj" uniqKey="Kozal M" first="Mj" last="Kozal">Mj Kozal</name><affiliation><nlm:aff id="A5">Yale University School of Medicine and Veterans Affairs Connecticut Healthcare System, New Haven, CT, USA</nlm:aff></affiliation></author><author><name sortKey="Johnson, Ma" sort="Johnson, Ma" uniqKey="Johnson M" first="Ma" last="Johnson">Ma Johnson</name><affiliation><nlm:aff id="A6">The Royal Free Hospital and University College London, UK</nlm:aff></affiliation></author><author><name sortKey="Jacoby, S" sort="Jacoby, S" uniqKey="Jacoby S" first="S" last="Jacoby">S. Jacoby</name><affiliation><nlm:aff id="A7">The Kirby Institute, University of New South Wales, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Llibre, Jm" sort="Llibre, Jm" uniqKey="Llibre J" first="Jm" last="Llibre">Jm Llibre</name><affiliation><nlm:aff id="A8">Univ Hospital Germans Trias i Pujol/”Lluita contra la SIDA” Foundation, Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Lundgren, J" sort="Lundgren, J" uniqKey="Lundgren J" first="J" last="Lundgren">J. Lundgren</name><affiliation><nlm:aff id="A9">Copenhagen HIV Programme, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25711326</idno><idno type="pmc">4341921</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341921</idno><idno type="RBID">PMC:4341921</idno><idno type="doi">10.1111/hiv.12236</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">001961</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001961</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment trial</title><author><name sortKey="Baxter, Jd" sort="Baxter, Jd" uniqKey="Baxter J" first="Jd" last="Baxter">Jd Baxter</name><affiliation><nlm:aff id="A1">Cooper University Hospital/Cooper Medical School of Rowan University, Camden, NJ, USA</nlm:aff></affiliation></author><author><name sortKey="Dunn, D" sort="Dunn, D" uniqKey="Dunn D" first="D" last="Dunn">D. Dunn</name><affiliation><nlm:aff id="A2">Medical Research Council Clinical Trials Unit at UCL, London, UK</nlm:aff></affiliation></author><author><name sortKey="White, E" sort="White, E" uniqKey="White E" first="E" last="White">E. White</name><affiliation><nlm:aff id="A2">Medical Research Council Clinical Trials Unit at UCL, London, UK</nlm:aff></affiliation></author><author><name sortKey="Sharma, S" sort="Sharma, S" uniqKey="Sharma S" first="S" last="Sharma">S. Sharma</name><affiliation><nlm:aff id="A3">Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA</nlm:aff></affiliation></author><author><name sortKey="Geretti, Am" sort="Geretti, Am" uniqKey="Geretti A" first="Am" last="Geretti">Am Geretti</name><affiliation><nlm:aff id="A4">Institute of Infection and Global Health, University of Liverpool, UK</nlm:aff></affiliation></author><author><name sortKey="Kozal, Mj" sort="Kozal, Mj" uniqKey="Kozal M" first="Mj" last="Kozal">Mj Kozal</name><affiliation><nlm:aff id="A5">Yale University School of Medicine and Veterans Affairs Connecticut Healthcare System, New Haven, CT, USA</nlm:aff></affiliation></author><author><name sortKey="Johnson, Ma" sort="Johnson, Ma" uniqKey="Johnson M" first="Ma" last="Johnson">Ma Johnson</name><affiliation><nlm:aff id="A6">The Royal Free Hospital and University College London, UK</nlm:aff></affiliation></author><author><name sortKey="Jacoby, S" sort="Jacoby, S" uniqKey="Jacoby S" first="S" last="Jacoby">S. Jacoby</name><affiliation><nlm:aff id="A7">The Kirby Institute, University of New South Wales, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Llibre, Jm" sort="Llibre, Jm" uniqKey="Llibre J" first="Jm" last="Llibre">Jm Llibre</name><affiliation><nlm:aff id="A8">Univ Hospital Germans Trias i Pujol/”Lluita contra la SIDA” Foundation, Barcelona, Spain</nlm:aff></affiliation></author><author><name sortKey="Lundgren, J" sort="Lundgren, J" uniqKey="Lundgren J" first="J" last="Lundgren">J. Lundgren</name><affiliation><nlm:aff id="A9">Copenhagen HIV Programme, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</nlm:aff></affiliation></author></analytic><series><title level="j">HIV medicine</title><idno type="ISSN">1464-2662</idno><idno type="eISSN">1468-1293</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Introduction</title><p id="P1">HIV-1 transmitted drug resistance (TDR) in treatment-naïve individuals is a well-described phenomenon. Baseline genotypic resistance testing is considered standard of care in most developed areas of the world.</p></sec><sec id="S2"><title>Methods</title><p id="P2">In the Strategic Timing of AntiRetroviral Treatment (START) trial, baseline genotypic resistance testing results were collected at study entry and analysed centrally to determine the prevalence of TDR in the study population. Resistance was based on a modified 2009 World Health Organization definition to reflect newer resistance mutations.</p></sec><sec id="S3"><title>Results</title><p id="P3">Baseline resistance testing was available in 1946 study participants. Higher rates of testing occurred in Europe (86.7%), the United States (81.3%), and Australia (89.9%) as compared to Asia (22.2%), South America (1.8%), and Africa (0.1%). The overall prevalence of TDR was 10.1%, most commonly to non-nucleoside reverse transcriptase inhibitors (4.5%) and nucleoside reverse transcriptase inhibitors (4%) compared to protease inhibitors (2.8%). The most frequent TDR mutations observed were M41L, D67N/G/E, T215F/Y/I/S/C/D/E/V/N, 219Q/E/N/R, K103N/S, and G190A/S/E in reverse transcriptase, and M46I/L and L90M in protease. By country, prevalence of TDR was highest in Australia (17.5%), France (16.7%), the United States (12.6%), and Spain (12.6%). No participant characteristics were identified as predictors for the presence of TDR.</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">START participants enrolled in resource-rich areas of the world were more likely to have baseline resistance testing. In Europe, the United States, and Australia, TDR prevalence rates varied by country.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">100897392</journal-id><journal-id journal-id-type="pubmed-jr-id">26808</journal-id><journal-id journal-id-type="nlm-ta">HIV Med</journal-id><journal-id journal-id-type="iso-abbrev">HIV Med.</journal-id><journal-title-group><journal-title>HIV medicine</journal-title></journal-title-group><issn pub-type="ppub">1464-2662</issn><issn pub-type="epub">1468-1293</issn></journal-meta><article-meta><article-id pub-id-type="pmid">25711326</article-id><article-id pub-id-type="pmc">4341921</article-id><article-id pub-id-type="doi">10.1111/hiv.12236</article-id><article-id pub-id-type="manuscript">NIHMS648139</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baxter</surname><given-names>JD</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dunn</surname><given-names>D</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>E</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Geretti</surname><given-names>AM</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kozal</surname><given-names>MJ</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>MA</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Jacoby</surname><given-names>S</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Llibre</surname><given-names>JM</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lundgren</surname><given-names>J</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><on-behalf-of>for the INSIGHT START Study Group</on-behalf-of></contrib-group><aff id="A1"><label>1</label>Cooper University Hospital/Cooper Medical School of Rowan University, Camden, NJ, USA</aff><aff id="A2"><label>2</label>Medical Research Council Clinical Trials Unit at UCL, London, UK</aff><aff id="A3"><label>3</label>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA</aff><aff id="A4"><label>4</label>Institute of Infection and Global Health, University of Liverpool, UK</aff><aff id="A5"><label>5</label>Yale University School of Medicine and Veterans Affairs Connecticut Healthcare System, New Haven, CT, USA</aff><aff id="A6"><label>6</label>The Royal Free Hospital and University College London, UK</aff><aff id="A7"><label>7</label>The Kirby Institute, University of New South Wales, Sydney, Australia</aff><aff id="A8"><label>8</label>Univ Hospital Germans Trias i Pujol/”Lluita contra la SIDA” Foundation, Barcelona, Spain</aff><aff id="A9"><label>9</label>Copenhagen HIV Programme, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</aff><author-notes><corresp id="FN1">Corresponding Author: John D. Baxter, M.D., Professor of Medicine, Division of Infectious Diseases, Cooper University Hospital, Cooper Medical School of Rowan University, 401 Haddon Avenue, Room 270, Camden, NJ 08103, Tel: (856) 757-7767, Fax: (856) 757-7803, <email>baxter@rowan.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>25</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>4</month><year>2016</year></pub-date><volume>16</volume><issue>0 1</issue><fpage>77</fpage><lpage>87</lpage><pmc-comment>elocation-id from pubmed: 10.1111/hiv.12236</pmc-comment>
<abstract><sec id="S1"><title>Introduction</title><p id="P1">HIV-1 transmitted drug resistance (TDR) in treatment-naïve individuals is a well-described phenomenon. Baseline genotypic resistance testing is considered standard of care in most developed areas of the world.</p></sec><sec id="S2"><title>Methods</title><p id="P2">In the Strategic Timing of AntiRetroviral Treatment (START) trial, baseline genotypic resistance testing results were collected at study entry and analysed centrally to determine the prevalence of TDR in the study population. Resistance was based on a modified 2009 World Health Organization definition to reflect newer resistance mutations.</p></sec><sec id="S3"><title>Results</title><p id="P3">Baseline resistance testing was available in 1946 study participants. Higher rates of testing occurred in Europe (86.7%), the United States (81.3%), and Australia (89.9%) as compared to Asia (22.2%), South America (1.8%), and Africa (0.1%). The overall prevalence of TDR was 10.1%, most commonly to non-nucleoside reverse transcriptase inhibitors (4.5%) and nucleoside reverse transcriptase inhibitors (4%) compared to protease inhibitors (2.8%). The most frequent TDR mutations observed were M41L, D67N/G/E, T215F/Y/I/S/C/D/E/V/N, 219Q/E/N/R, K103N/S, and G190A/S/E in reverse transcriptase, and M46I/L and L90M in protease. By country, prevalence of TDR was highest in Australia (17.5%), France (16.7%), the United States (12.6%), and Spain (12.6%). No participant characteristics were identified as predictors for the presence of TDR.</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">START participants enrolled in resource-rich areas of the world were more likely to have baseline resistance testing. In Europe, the United States, and Australia, TDR prevalence rates varied by country.</p></sec></abstract><kwd-group><kwd>HIV</kwd><kwd>drug resistance</kwd><kwd>antiretroviral therapy</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001961 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001961 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.32. |  |